ChemicalBook > CAS DataBase List > CEP-18770

CEP-18770

Product Name
CEP-18770
CAS No.
847499-27-8
Chemical Name
CEP-18770
Synonyms
CS-252;CT 47098;CEP-18770;CIP 18770;NPH 007098;Delanzomib;Delanzomib, >=98%;CEP-18770 (DelanzoMib);DelanzoMib (CEP-18770);DelanzoMib, Free Base, >99%
CBNumber
CB42570998
Molecular Formula
C21H28BN3O5
Formula Weight
413.28
MOL File
847499-27-8.mol
More
Less

CEP-18770 Property

Melting point:
178-190°C (dec.)
Density 
1.207
storage temp. 
Hygroscopic, -20°C Freezer, Under Inert Atmosphere
solubility 
Acetonitrile (Slightly), Chloroform (Slightly), Methanol (Slightly)
form 
Solid
pka
9.67±0.43(Predicted)
color 
White to Off-White
Stability:
Hygroscopic
More
Less

Safety

HS Code 
29333990
More
Less

Hazard and Precautionary Statements (GHS)

More
Less

N-Bromosuccinimide Price

Cayman Chemical
Product number
23557
Product name
Delanzomib
Purity
≥95%
Packaging
1mg
Price
$32
Updated
2024/03/01
Cayman Chemical
Product number
23557
Product name
Delanzomib
Purity
≥95%
Packaging
5mg
Price
$122
Updated
2024/03/01
Cayman Chemical
Product number
23557
Product name
Delanzomib
Purity
≥95%
Packaging
10mg
Price
$214
Updated
2024/03/01
Cayman Chemical
Product number
23557
Product name
Delanzomib
Purity
≥95%
Packaging
50mg
Price
$911
Updated
2024/03/01
Usbiological
Product number
007917
Product name
Delanzomib
Packaging
5mg
Price
$602
Updated
2021/12/16
More
Less

CEP-18770 Chemical Properties,Usage,Production

Description

Delanzomib is an orally bioavailable inhibitor of chymotrypsin-like proteasome activity (IC50 = 3.8 nM in isolated human erythrocytes) that only marginally inhibits tryptic and peptidyl glutamyl proteasome activity. Delanzomib pre-treatment (20 nM) in vitro inhibits IκBα degradation, NF-κB activation, and the expression of NF-κB-regulated genes, including IκBα, XIAP, TNF-α, IL-1β, ICAM-1, and VEGF. Delanzomib induces apoptosis in multiple myeloma cell lines and inhibits proliferation in a panel of human hematologic and solid tumor cell lines (IC50s = 5.6-34.2 nM). It reduces tumor weight in an RPMI 8226 human multiple myeloma mouse xenograft model when administered intravenously at doses ranging from 1.5-4 mg/kg twice daily and leads to complete tumor regression at a chronic oral dose of 13 mg/kg. Delanzomib reduces the serum level of circulating cytokines, prevents renal tissue damage, and increases lifespan in a mouse model of fatal lupus nephritis.

Uses

Delanzomib is an orally active proteasome inhibitor. Delanzomib has been shown to down-modulate NF-κB, induce apoptosis, inhibit angiogenesis and M-CSF-RANKL-induced osteoclastogenesis.

Definition

ChEBI: Delanzomib is a C-terminal boronic acid peptide inhibitor which induces apoptosis in multiple myeloma, hematological and solid tumor cell lines. It has a role as a proteasome inhibitor, an apoptosis inducer and an antineoplastic agent. It is a threonine derivative, a phenylpyridine, a C-terminal boronic acid peptide and a secondary alcohol. It is functionally related to a L-threonine.

target

proteasome

CEP-18770 Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

CEP-18770 Suppliers

Canada 1 China 102 United States 16 Global 119
Toronto Research Chemicals
Tel
--
Fax
--
Email
info@trc-canada.com
Country
Canada
ProdList
6038
Advantage
71
More
Less

View Lastest Price from CEP-18770 manufacturers

Zhuozhou Wenxi import and Export Co., Ltd
Product
Delanzomib 847499-27-8
Price
US $15.00-10.00/KG
Min. Order
1KG
Purity
99%+ HPLC
Supply Ability
Monthly supply of 1 ton
Release date
2021-07-10
Zhuozhou Wenxi import and Export Co., Ltd
Product
Delanzomib 847499-27-8
Price
US $15.00-10.00/KG
Min. Order
1KG
Purity
99%+ HPLC
Supply Ability
Monthly supply of 1 ton
Release date
2021-07-09
Career Henan Chemical Co
Product
CEP-18770 847499-27-8
Price
US $2.00/KG
Min. Order
1KG
Purity
99
Supply Ability
100kg
Release date
2020-01-07

847499-27-8, CEP-18770Related Search:

CPI-455 Maritoclax GDC-0623 IMR-1 CHIR 99021 trihydrochloride LJI308 2-((2-Chlorophenyl)(phenyl)aMino)-N-(7-(hydroxyaMino)-7-oxoheptyl)pyriMidine-5-carboxaMide AZ191 HTH-01-015 GDC-0879 4-iodo-3-nitrobenzamide VBY-825 Bortezomib MLN9708 MK-2206 2HCl (R)-1-(2-(2,5-dichlorobenzamido)acetamido)-3-methylbutylboronic acid Oprozomib Carfilzomib

  • CEP-18770
  • [(1R)-1-[[(2S,3R)-3-Hydroxy-2-[[(6-phenylpyridin-2-yl)carbonyl]amino]-1-oxobutyl]amino]-3-methylbutyl]boronic acid
  • CIP 18770
  • CT 47098
  • Delanzomib
  • NPH 007098
  • CEP-18770 (DelanzoMib)
  • DelanzoMib, Free Base, >99%
  • ((R)-1-((2S,3R)-3-Hydroxy-2-(6-phenylpicolinaMido)butanaMido)-3-Methylbutyl)boronic acid
  • (R)-1-((2S,3R)-3-hydroxy-2-(2-phenylpicolinamido)butanamido)-3-methylbutan-2-ylboronic acid
  • Delanzomib [(1R)-1-[[(2S,3R)-3-Hydroxy-2-[[(6-phenylpyridin-2-yl)carbonyl]amino]-1-oxobutyl]amino]-3-methylbutyl]boronic acid
  • Delanzomib, >=98%
  • DelanzoMib (CEP-18770)
  • Boronic acid, B-[(1R)-1-[[(2S,3R)-3-hydroxy-1-oxo-2-[[(6-phenyl-2-pyridinyl)carbonyl]aMino]butyl]aMino]-3-Methylbutyl]-
  • CEP-18770;CEP 18770;CEP18770
  • CS-252
  • (1R)-1-[(2S,3R)-3-hydroxy-2-[(6-phenylpyridin-2-yl)formamido]butanamido]-3-methylbutyl]boronic acid
  • ((R)-1-((2S,3R)-3-hydroxy-2-(6-phenylpicolinamido)butanamido)-3-methylbutan-2-yl)boronic acid
  • 847499-27-8
  • C21H28BN3O5
  • Inhibitor
  • Inhibitors